
Tissue Testing Technologies LLC (AKA: T3LLC~T3 LLC) Profile last edited on: 11/10/2017
CAGE: 7AC31
UEI: ZSY2J1RRALT5
Business Identifier: Development of cryopreservation methods to provide human cell-based in vitro systems for high throughput screening purposes Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
2231 Technical Parkway Suite A
North Charleston, SC 29406
North Charleston, SC 29406
(843) 514-6164 |
N/A |
www.t3-tissuetestingtechnologies.com |
Location: Single
Congr. District: 06
County: Charleston
Congr. District: 06
County: Charleston
Public Profile
Created by principles, and IP, of Cell and Tissue Systems, the primary focus of T3LLC is on low cost to market development of cryopreservation methods to provide human cell-based in vitro systems for high throughput screening purposes. T3 utilizes proprietary methods for preservation of human cell-derived monolayers and 3D cultures in multiwell plates. T3 is positioned to take advantage of the current trend away from animal testing for cosmetics, household chemicals and drugs by providing cryopreserved human cell-based tissue equivalents in place of current practice just in time manufacturing. The longer-term focus of T3LLC is research and development of ice-free cryopreservation methods for clinical applications. Such applications include major internal organs, larynx, trachea, abdominal wall, knee tissues, skeletal muscles, facial tissues and limb extremities, as well as critical natural and engineered tissues such as skin, heart valves and blood vessels. T3LLC also offers consulting and contract research services to commercial and academic organizations with an emphasis on living biological material transport and cryopreservation.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 1 | NIH | $610,972 | |
Project Title: Evaluation of growth potential of ice-free vitrified heart valves in a pediatric porcine model. | ||||
2023 | 1 | NIH | $302,037 | |
Project Title: Ice-free vitrification and nanowarming of meniscal grafts for transplantation | ||||
2022 | 1 | NIH | $385,522 | |
Project Title: Mechanistic approach to optimization of a kidney preservation solution | ||||
2022 | 2 | NIH | $2,045,742 | |
Project Title: ICE-Free Vitrification and Nano Warming Technology for Banking of Cardiovascular Structures | ||||
2021 | 1 | NIH | $339,546 | |
Project Title: Extended limb preservation employing an optimization strategy for stabilization. |
Key People / Management
Kevin G M Brockbank -- President; Chief Science Officer
Lia H Campbell -- Research Director
Taufiek Konrad Rajabi
Lia H Campbell -- Research Director
Taufiek Konrad Rajabi
Company News
There are no news available.